China Cord Blood Corporation (NYSE:CO) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 501,050 shares, a decrease of 34.2% from the August 31st total of 761,211 shares. Based on an average daily trading volume, of 294,642 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.6% of the company’s shares are short sold.

Separately, BidaskClub upgraded China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 1st.

Shares of China Cord Blood Corporation (NYSE:CO) opened at 11.55 on Wednesday. China Cord Blood Corporation has a 52-week low of $4.27 and a 52-week high of $14.95. The stock’s 50 day moving average price is $12.38 and its 200-day moving average price is $9.60. The company has a market cap of $1.31 billion, a P/E ratio of 36.90 and a beta of 0.89.

China Cord Blood Corporation (NYSE:CO) last posted its earnings results on Wednesday, August 23rd. The medical research company reported $0.09 EPS for the quarter. China Cord Blood Corporation had a net margin of 22.07% and a return on equity of 8.64%. The firm had revenue of $33.07 million during the quarter. Equities analysts expect that China Cord Blood Corporation will post $0.15 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in CO. MML Investors Services LLC bought a new position in China Cord Blood Corporation in the 2nd quarter valued at approximately $104,000. Parametrica Management Ltd acquired a new stake in China Cord Blood Corporation in the second quarter valued at approximately $149,000. Virtu KCG Holdings LLC acquired a new stake in China Cord Blood Corporation in the second quarter valued at approximately $199,000. Spark Investment Management LLC acquired a new stake in China Cord Blood Corporation in the first quarter valued at approximately $204,000. Finally, Citadel Advisors LLC acquired a new stake in China Cord Blood Corporation in the second quarter valued at approximately $208,000. Institutional investors and hedge funds own 13.33% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/short-interest-in-china-cord-blood-corporation-co-declines-by-34-2.html.

About China Cord Blood Corporation

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with MarketBeat.com's FREE daily email newsletter.